Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients

Study (n=11,534) found acute kidney injury (IRR 1.42, 95% CI: 1.01-2.00), liver monitoring suggestive of hepatic damage (3.06, 95% CI: 2.66-3.53),and AF (1.12, 95% CI: 1.05-1.19) were significantly more often observed with abiraterone than with enzalutamide.

British Journal of Clinical Pharmacology